Juan Vera - 31 Oct 2025 Form 4 Insider Report for Marker Therapeutics, Inc. (MRKR)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: MRKR
Reported as of: 31 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Nov 2025, 17:03:27 UTC
Prior SEC filing: 14 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Julio C. Esquivel as Attorney-In-Fact for Juan Vera

Key filing fact

Juan Vera filed Form 4 for Marker Therapeutics, Inc. (MRKR) on 04 Nov 2025.

Key facts

This page summarizes Juan Vera's Form 4 filing for Marker Therapeutics, Inc. (MRKR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Nov 2025, 17:03.

Change

Previous filing in this sequence was filed on 14 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001755495 Primary reporting owner

Vera Juan

Relationship: Chief Executive Officer, Director
Address: MARKER THERAPEUTICS, INC., 2450 HOLCOMBE BLVD, TMC PARTNERS OFFICE, HOUSTON
Signature: /s/ Julio C. Esquivel as Attorney-In-Fact for Juan Vera
Signature date: 04 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRKR transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +250,000
Change %
Price: $0.000000
Shares after: 250,000
Date: 31 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 250,000
Exercise price: $0.9877
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One fourth of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second, third and fourth anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, October 31, 2025.